The conditions for Xspray Pharma’s listing on Nasdaq Stockholm have been fulfilled

Regulatory press release 2020-03-26

STOCKHOLM – March 26, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020, that the company had received clearance for a listing on Nasdaq Stockholm, following the fulfilment of customary conditions. Xspray Pharma has today received information that the conditions have been fulfilled and accordingly, Xspray Pharma’s first day of trading on Nasdaq Stockholm’s main market is March 27, 2020. The last day of trading on Nasdaq First North Growth Market is March 26, 2020.

For further information, please contact:

Per Andersson, CEO, Xspray Pharma AB

Phone: +46 (0) 706 88 23 48



The information was sent for publication, through the agency of the contact person set out above, on March 26, 2020, at 3.15 p.m. CET.


About Xspray Pharma

Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.

The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq First North Growth Market Stockholm.


Redeye AB is Xspray Pharma’s Certified Adviser

+46 (0) 8 121 576 90